Non-peptide GnRH agents, pharmaceutical compositions and methods for their use
Patent 6903132 Issued on June 7, 2005. Estimated Expiration Date: June 11, 2023. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/461, The hetero ring is five-membered549/429, The hetero ring is five-membered549/483, Having -C(=X)-, wherein X is chalcogen, bonded directly to the hetero ring549/487, Nitrogen bonded directly to the -C(=X)- group544/212, Hetero ring544/242, 1,3-diazines544/297, Nitrogen attached directly at 2-position by nonionic bonding and sulfur bonded directly to the nitrogen546/268.1, Additional hetero ring containing546/276.4, The additional hetero ring is five-membered consisting of one nitrogen and four carbons546/283.4, The additional hetero ring is five-membered514/303, Exactly three ring nitrogens in the bicyclo ring system514/617R contains benzene ring
Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
Other References
Millet, et al., “Antitrypanosomal Activities and Cytotoxicity of 5-Nitro-2-furancarbohydrazides,” Bioorganic and Medicinal Chemistry Letters, 2002, 3601-3604, vol. 12.
Perrier, et al., “Mimicking dominant Negative Inhibition of Prion Replication through Structure-based Drug Design,” Proc. National Acad. Of Science, 2002, 6073-6078, vol. 97, No. 11.
Abdel-Magid, et al., “Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride,” J. Org. Chem., 1996, pp. 3849, vol. 61.
Anastasis, et al., “Analogues of Antijuvenile Hormones”, J. Chem. Soc. Perkin Trans. I, 1982, p. 2013.
Bagshawe, et al., “Antibody-Directed Enzyme Prodrug Therapy: A Review”, Drug Dev. Res., 1995, pp. 220-230, vol. 34.
Bertolini, et al., “A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug”, J. Med. Chem., 1997, pp. 2011-2016, vol. 40.
Bodor, “Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems”, Advances in Drug Res., 1984, pp. 224-231, vol. 13.
Bowers, et al., “On the Inhibitory Effects of Luteinizing Hormone-Releasing Hormone Analogs”, Endocrinology, 1980, pp. 675-683 (in vitro).
Bundgaard, Design of Prodrugs, (1985, Elsevier Press; Amsterdam—New York—Oxford).
Cheng, et al., “Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I50) of an Enzymatic Reaction★”, Biochemical Pharmacol., 1973, pp. 3099-3108, vol. 22.
Cho, et al., “Discovery of a Novel, Potent, and Orally Active Nonpeptide Antagonist of the Human Luteinizing Hormone-Releasing Hormone (LHRH) Receptor”, J. Med. Chem., 1998, pp. 4190-4195, vol. 41(22).
Corbin, et al., “Inhibition of the Pre-Ovulatory Proestrous Gonadotropin Surge, Ovulation and Pregnancy with a Peptide Analogue of Luteinizing Hormone Releasing Hormone”, Endocr. Res. Commun., 1975, pp. 1-23, vol. 2.
Dear, et al., “Mass Directed Peak Selection, An Efficient Method of Drug Metabolite Identification Using Directly Coupled Liquid Chromatography-Mass Spectrometry-Nuclear Magnetic Resonance Spectroscopy”, J. Chromatogr. B., 2000, pp. 281-293, vol. 748.
Goetz, “Research Letters: Decreased Recovery of CD4 Lymphocytes in Older HIV-infected Patients Beginning Highly Active Antiretroviral Therapy”, AIDS, 2001, pp. 1576-1578, vol. 15.
Harms, et al. “A Rapid and Simple Procedure for Chronic Cannulation of the Rat Jugular Vein”, Applied Physiol, 1974, pp. 391-392, vol. 36(3).
Jungwirth, et al., “Luteinizing Hormone-Releasing Hormone Antagonist Cetrorelix (SB-75) and Bombesin Antagonist RC-3940-II Inhibit the Growth of Androgen-Independent PC-3 Prostate Cancer in Nude Mice”, Prostate, 1997, pp. 164-172, vol. 32(3).
Koppan, et al., “Targeted Cytotoxic Analog of Luteinizing Hormone-Releasing Hormone AN-207 Inhibits the Growth of PC-82 Human Prostate Cancer in Nude Mice”, Prostate, 1999, pp. 151-158, vol. 38(2).
Kottler, et al., “The Genes for Gonadotropin-Releasing Hormone and Its Receptor and Expressed in Human Breast with Fibrocystic Disease and Cancer”, Int. J. Cancer, 1997, pp. 595-599, vol. 71(4).
Larsen, “Design and Application of Prodrugs”, Drug Design and Development, (1991, Krogsgaard-Larsen et al eds., Harwood Academic Publishers).
Montagnani, et al. “Effects of LHRH Agonists on the Growth of Human Prostatic Tumor Cells: ‘In Vitro’ and ‘In Vivo’ Studies”, Arch. Ital. Urol. Androl., 1997, pp. 257-263, vol. 69(4).
Nagy, et al., “Stability of Cytotoxic Luteinizing Hormone-Releasing Hormone Conjugate (AN-152) Containing Doxorubicin 14-O-Hemiglutarate in Mouse and Human Serum in Vitro: Implications for the Design of Preclinical Studies”, Proc Natl Acad Sci USA, 2000, pp. 829-834, vol. 97(2).
Norwood Abbey Press Release dated Mar. 5, 2001; “Norwood Abbey Announces Breakthrough in Immunology”.
Prox, et al., “Rapid Structure Elucidation of Drug Metabolites by Use of Stable Isotopes”, Xenobiol., 1992, pp. 103-112, vol. 3(2).
Shan, et al., “Prodrug Strategies Based on Intramolecular Cyclization Reactions”, J. Pharm. Sci., 1997, pp. 765-767, vol. 86(7).
Spraul, et al., “Liquid Chromatography Coupled with High-Field Proton NMR for Profiling Human Urine for Endogenous Compounds and Drug Metabolites”, J. Pharmaceutical & Biomedical Analysis, 1992, pp. 601-605, vol. 10(8).
Srkalovic, et al., “Presence and Characteristics of Receptors for [D-Trp 6] Luteinizing Hormone Releasing Hormone and Epidermal Growth Factor in Human Ovarian Cancer”, Int. J. Oncol., 1998, pp. 489-498, vol. 12(3).
Still, et al., “Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution”, A.J. Org. Chem., 1978, p. 2923, vol. 43.
Walsh, et al., “Potent Antagonists of Gonadotropin Releasing Hormone Receptors Derived from Quinolone-6-Carboxamides”, Bioorg & Med Chem Ltrs., 2000, pp. 443-447, vol. 10.
Wilt, et al., “Ring Size Effects in the Neophyl Rearrangement. II. The Decarbonylation of (1-Methylindanyl)acetaldehyde 1,2”, J. Org. Chem., 1961, p. 4196, vol. 26.
June 11, 2023. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
